Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results on Wednesday for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). “We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability," David Pidduck, the company's CEO said. "The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats.” Read Also: Cannabinoids-Focused Pharma Company, MediPharm, Sees ...